Characteristics | Values |
---|---|
Demographic | |
Age at inclusion, yrs, mean (SD) | 58.3 (10.0) |
Female, n (%) | 467 (69) |
Cardiovascular risk factors | |
Diabetes, n (%) | 43 (6.4) |
Current smoking, n (%) | 188 (28) |
Systolic BP, mmHg, mean (SD) | 144 (20) |
Diastolic BP, mmHg, mean (SD) | 83 (10) |
Antihypertensive treatment, n (%) | 163 (20) |
Antihypertensive treatment and/or BP > 140/90, n (%) | 356 (53) |
Cholesterol, mmol/l, mean (SD) | 5.69 (1.11) |
HDL cholesterol, mmol/l, mean (SD) | 1.52 (0.49) |
Triglycerides, mmol/l, mean (SD) | 1.48 (0.71) |
Statin treatment, n (%) | 45 (6.7) |
Statin treatment and/or hyperlipidemia, n (%) | 495 (73) |
BMI, kg/m2, mean (SD) | 26.8 (4.3) |
RA variables | |
ESR, mm/h, median (IQR) | 24 (12–40) |
CRP, mg/l, median (IQR) | 10 (7–26) |
CDAI, median (IQR) | 21 (13–30) |
CDAI > 10, n (%) | 569 (85.6) |
Tender joint count, n, median (IQR) | 5 (2–9) |
Swollen joint count, n, median (IQR) | 6 (3–10) |
DAS28, median (IQR) | 4.7 (3.7–5.6) |
HAQ median (IQR) | 0.75 (0.38–1.25) |
HAQ > 0.5, n (%) | 456 (68.6) |
Patient global VAS, mm, median (IQR) | 45 (23–64) |
Positive anti-CCP, n (%) | 423/611 (69) |
Corticosteroids, n (%) | 342 (51.4) |
RA: rheumatoid arthritis; BP: blood pressure; HDL: high-density lipoproteins; BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CDAI: Clinical Disease Activity Index; DAS28: 28-joint count Disease Activity Score; HAQ: Health Assessment Questionnaire; VAS: visual analog scale; anti-CCP: anticyclic citrullinated peptide antibodies; IQR: interquartile range.